Exploring neurokinin-1 receptor antagonism for depression with structurally differentiated inhibitors

Area of Science:

• Neuroscience
• Pharmacology
• Computational Chemistry

Background:

• Neurokinin-1 receptor (NK1R) is a potential target for major depressive disorder (MDD) due to its role in stress and neuroinflammation.
• Previous NK1R antagonists yielded inconsistent clinical results, possibly due to their chemical structure (3,5-bis-trifluoromethylphenyl moiety).
• The therapeutic potential of structurally distinct NK1R antagonists remains unexplored.

Purpose of the Study:

• To identify and evaluate novel NK1R antagonists lacking the 3,5-bis-trifluoromethylphenyl group.
• To assess the antidepressant potential of these structurally diverse compounds in preclinical models.
• To investigate the binding mode of a promising novel antagonist using computational simulations.

Main Methods:

• Computational approaches were used to identify NK1R antagonists.
• Preclinical models of depression were employed to evaluate compound efficacy.
• Molecular docking and molecular dynamics simulations were performed to analyze binding interactions.

Main Results:

• Several novel NK1R antagonists demonstrated efficacy in reducing depressive-like behaviors.
• Compound #15 exhibited the most significant antidepressant effects in preclinical models.
• Molecular simulations revealed a unique binding mode for compound #15, involving hydrogen bonding and π-π stacking.

Conclusions:

• Structurally diverse NK1R antagonists hold potential for modulating behavior and neuroinflammation in MDD.
• Novel chemical scaffolds may overcome limitations associated with previous NK1R antagonists.
• Further investigation is warranted to determine the clinical relevance of these findings for major depressive disorder treatment.